Individuals treated with riociguat for pulmonary hypertension may have a greater risk for gastrointestinal disorders compared with tadalafil and sildenafil.
Brain natriuretic peptide levels may accurately predict 5-year survival rates in patients with pulmonary arterial hypertension.
Although the Wells and revised Geneva scores are used in the general population to predict pulmonary embolism, researchers found they were not reliable in pregnant and postpartum women.
Pulmonary hemodynamic changes in chronic thromboembolic pulmonary hypertension may be monitored via the 6-minute walk test.
Bosentan may benefit a subset of patients with idiopathic pulmonary fibrosis-associated pulmonary hypertension.
A clinical trial is underway to assess the safety and efficacy of dabigatran in intermediate-risk pulmonary embolism after completing 72 hours of heparin therapy.
The REVEAL risk score gives significant predictive value for long-term survival and changes in mortality risk in patients with PAH.
A fully implantable programmable intravascular delivery system using treprostinil was found to be highly stable in patients with PAH.
Pulmonary hypertension may be more important than age in predicting heart transplant outcomes.
A study evaluated whether changes in estimated glomerular filtration rate were predictive of mortality in patients with pulmonary arterial hypertension.
Prospective validation research is needed before these clinical predictors of pediatric PE can become guidelines.
A systematic review evaluated whether catheter-directed thrombolysis improved outcomes in patients with intermediate-risk pulmonary emboli.
The use of veno-arterial extracorporeal membrane oxygenation as bridge therapy for massive pulmonary embolism may allow clinicians to better triage patients to appropriate destination therapy.
Individuals who are HIV-positive may be at a higher risk for increased pulmonary pressure and mortality.
A study evaluated the quality of targeted anticoagulation in patients with PAH, and examined outcomes associated with poor time spent within targeted anticoagulation range.
Lung transplantation may be an option in patients with severe pulmonary arterial hypertension who do not respond well to medical therapy.
Select pediatric patients with pulmonary arterial hypertension may benefit from treatment with riociguat.
A 40-year-old woman presents with worsening shortness of breath after being treated with long-acting nifedipine for 2 years.
Hemodynamics may improve in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty with complication rates comparable to pulmonary endarterectomy.
Study results confirm the benefits of exercise vs granulocyte-macrophage colony-stimulating factor in improving 6-minute walk test in PAD.
Using biomarkers in pulmonary arterial hypertension may be a less invasive strategy for assessing response to treatment.
Pulmonary and thoracic symptoms often coincide with initial presentation of connective tissue disease.
Pulmonary arterial hypertension is becoming a major cause of death in patients with systemic sclerosis.
Results show statistically significant differences between SSc-PAH groups and iPAH groups for variables including age, sex, FVC capacity, total lung capacity, and FEV1, among others.
Patients with pulmonary arterial hypertension have reduced cerebrovascular reactivity to CO2.
Respiratory muscle dysfunction, iron deficiency, and skeletal muscle dysfunction have been implicated as mechanisms for exercise intolerance in pulmonary arterial hypertension.
The new device features a more ergonomic design with a single-button operation, an intuitive user interface to adjust breath counts, a rechargeable battery, and a display that guides patients through the inhalation process.
The frequency of eukaryotic translation initiation factor 2 alpha kinase 4 gene (EIF2AK4) mutations in patients with pulmonary arterial hypertension was investigated.
Borderline PH was linked to increased mortality after adjustment for 34 variables.
Patients who develop pulmonary edema after starting prostacyclin for pulmonary arterial hypertension have a greater risk for mortality.
Pulmonary vascular compliance may independently predict survival and prognosis in patients with pulmonary arterial hypertension associated with congenital heart disease.
Patients with pulmonary arterial hypertension experienced better improvements in pulmonary arterial compliance with riociguat compared with phosphodiesterase type 5 inhibitors.
Lung disease experts Athol Wells, MD, and Joshua Mooney, MD, MS, debate the diagnostic value of bronchoalveolar lavage in idiopathic pulmonary fibrosis.
Right ventricular epicardial vasculature is more extensive in patients with pulmonary arterial hypertension compared with individuals without disease.
Results indicate that further study of the relationship between the 6-minute walk distance test and functional capacity in PAH is necessary.
A study sought to describe the occurrence of different types of pulmonary hypertension in hereditary hemorrhagic telangiectasia.
Depression, anxiety, and reduced healthcare-related quality of life are common in patients with either pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
A 65-year-old man with COPD presents with worsening exertional dyspnea.
Methamphetamine-associated pulmonary arterial hypertension has a higher risk for clinical worsening compared with idiopathic pulmonary arterial hypertension.
Having at least 2 features of pulmonary veno-occlusive disease demonstrated a trend toward worse survival in patients with pulmonary arterial hypertension and systemic sclerosis.
Specific guidelines should be developed for the use of the 6-minute walk test in idiopathic pulmonary fibrosis.
Pulmonary arterial hypertension tends to vary in presentation in patients of different races and ethnicities.
Differences in right ventricular morphology may predict the hemodynamic nature of pulmonary hypertension.
Pulmonary endarterectomy is an effective and durable treatment for chronic thromboembolic pulmonary hypertension.
Prenatal factors such as intrauterine growth retardation, infection, and placental inflammation can affect lung development in neonates.
Influenza vaccination does not increase the risk for venous thromboembolism in patients older than 50 years of age.
Similar short-term outcomes were seen in patients with saddle and nonsaddle pulmonary embolism.
Patients undergoing pulmonary vasodilatory therapy were more functional at initial presentation.
The guidelines for PAD were updated.
Poor outcomes in pulmonary arterial hypertension may be linked to worsening right atrial function.
Charleston comorbidity index is an independent predictor of mortality in patients with hemodynamically stable pulmonary embolism.
The first FDA-approved drug for pediatric pulmonary arterial hypertension will be available in 32 mg tablets for oral suspension.
Researchers were able to successfully use a fully implantable delivery system for treprostinil for adult patients with pulmonary arterial hypertension.
A retrospective analysis demonstrated that the ratio of left to right ventricular end-diastolic pressures can predict outcomes in patients with PH.
New criteria by the American College of Radiology detail appropriateness of various imaging techniques for suspected pulmonary hypertension.
Computed tomography-derived pulmonary artery-to-aorta ratio can predict pulmonary artery pressure and survival in patients with idiopathic pulmonary fibrosis.
Meta-analysis supports anti-RNP and anti-Sm antibodies as serological biomarkers of PAH risk in patients with SLE.
MRI measures can predict outcomes in pulmonary arterial hypertension.
Pulmonary and genetics experts James E. Loyd, MD, and Wendy Chung, MD, PhD, offer insight into the role of genetics in pulmonary arterial hypertension.
Combination therapy with ambrisentan and tadalafil may improve response in patients with connective tissue disease-associated pulmonary arterial hypertension.